University of Texas Investment Managment Co. continued to hold its position in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,830,882 shares of the company’s stock at the end of the second quarter. Bio-Path Holdings makes up 4.3% of University of Texas Investment Managment Co.’s portfolio, making the stock its 8th largest position. University of Texas Investment Managment Co.’s holdings in Bio-Path Holdings were worth $1,456,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Legal & General Group Plc raised its stake in shares of Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Bio-Path Holdings during the first quarter worth $105,000. HighTower Advisors LLC raised its stake in shares of Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares in the last quarter. Sabby Management LLC raised its stake in shares of Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares in the last quarter. 21.38% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bio-Path Holdings, Inc. (BPTH) opened at 0.266 on Friday. The firm’s 50-day moving average is $0.36 and its 200-day moving average is $0.59. Bio-Path Holdings, Inc. has a 52 week low of $0.25 and a 52 week high of $1.70. The stock’s market capitalization is $26.61 million.

Bio-Path Holdings (NASDAQ:BPTH) last announced its earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Analysts forecast that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current fiscal year.

WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/18/university-of-texas-investment-managment-co-has-1456000-stake-in-bio-path-holdings-inc-bpth.html.

BPTH has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Bio-Path Holdings in a research note on Tuesday, July 4th. Zacks Investment Research lowered shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th.

About Bio-Path Holdings

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Want to see what other hedge funds are holding BPTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Path Holdings, Inc. (NASDAQ:BPTH).

Institutional Ownership by Quarter for Bio-Path Holdings (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.